This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Neurotensin (NTS)	<p><i>In vitro</i> and rodent studies suggest a conjugate of NTS and the brain-penetrating peptide Angiopep could help treat pain. In a mouse <i>in situ</i> model of brain penetration, the conjugate, dubbed ANG2002, had more than 10-fold better brain uptake than unconjugated NTS. In mouse models of acute pain or rat models of persistent, neuropathic and bone cancer-associated pain, i.v. delivery of ANG2002 decreased pain behaviors more potently than delivery of NTS alone or vehicle control. Next steps include IND-enabling studies and clinical testing.</p> <p>Angiochem Inc.'s ANG2002 is in preclinical development to treat pain.</p> <p>SciBX 7(10); doi:10.1038/scibx.2014.289 Published online March 13, 2014</p>	Angiopep and conjugates patented by Angiochem; patent application filed covering ANG2002; available for partnership	<p>Demeule, M. <i>et al. J. Clin. Invest.</i>; published online Feb. 17, 2014; doi:10.1172/JCI70647</p> <p>Contact: Philippe Sarret, University of Sherbrooke, Sherbrooke, Quebec, Canada e-mail: philippe.sarret@usherbrooke.ca</p>